Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary/gastrointestinal excretion rather than renal.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg once daily.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years of age).
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required for patients with renal impairment (creatinine clearance as low as 15 mL/min) or end-stage renal disease.
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* Hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* History of pancreatitis (use with caution).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or sulfonylureas).
* **Serious:** Acute pancreatitis (including fatal cases), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May significantly decrease linagliptin plasma concentrations, potentially reducing efficacy. Avoid use if possible; if necessary, monitor glycemic control closely.
## Monitoring
* **HbA1c:** Every 3–6 months.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain; discontinue if suspected.
* **Skin:** Monitor for blistering or erosions suggestive of bullous pemphigoid.
* **Blood Glucose:** Periodic self-monitoring of blood glucose (SMBG).
## Clinical Pearls
* **Renal Sparing:** Linagliptin is the only DPP-4 inhibitor that does not require renal dosage adjustment, making it a preferred choice for patients with chronic kidney disease.
* **Administration:** May be taken with or without food.
* **Hypoglycemia Risk:** Linagliptin alone has a low risk of hypoglycemia; however, when co-administered with a sulfonylurea or insulin, the dose of the secretagogue or insulin may need to be reduced to minimize the risk of hypoglycemia.
* **Incretin Mimetics:** Do not combine with GLP-1 receptor agonists (e.g., semaglutide, liraglutide) as both work via the incretin pathway; no additional glycemic benefit is expected.
***
**Disclaimer:** This information is for educational purposes only. Always verify prescribing information, contraindications, and drug-drug interactions with the most current official manufacturer labeling or a clinical pharmacology database before prescribing or administering medication.
